WM115Homo sapiens (Human)Cancer cell line

Also known as: WC00079, WM115mel, WM115-mel, WM115F, WM 115, WM-115, WH115mel

🤖 AI SummaryBased on 16 publications

Quick Overview

Human melanoma cell line with potential for research in cancer biology and drug development.

Detailed Summary

WM115 is a human melanoma cell line derived from a primary melanoma lesion. It is widely used in cancer research due to its characteristics related to melanoma progression and response to therapeutic agents. The cell line has been studied for its genetic and molecular features, including mutations in BRAF and NRAS, which are critical in melanoma development. Research on WM115 has contributed to understanding the role of these mutations in tumor growth and resistance to targeted therapies. Additionally, the cell line has been utilized in studies involving the MAPK and PI3K/AKT signaling pathways, which are key in melanoma pathogenesis. Its utility in preclinical studies makes it a valuable resource for developing and testing new cancer treatments.

Research Applications

Cancer biology researchDrug developmentGenetic and molecular studiesSignaling pathway analysis

Key Characteristics

BRAF and NRAS mutationsMAPK and PI3K/AKT pathway involvementPotential for therapeutic resistance studies
Generated on 6/14/2025

Basic Information

Database IDCVCL_0040
SpeciesHomo sapiens (Human)
Tissue SourceRight anterior leg, skin[UBERON:UBERON_0001511]

Donor Information

Age55
Age CategoryAdult
SexFemale

Disease Information

DiseaseMelanoma
LineageSkin
SubtypeMelanoma
OncoTree CodeMEL

DepMap Information

Source TypeATCC
Source IDACH-000304_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleBRAFp.Val600Asp (c.1799_1800delTGinsAT)Heterozygous-Unknown, Unknown, PubMed=29492214, PubMed=23851445, PubMed=19799798, PubMed=12068308, Wistar
Gene deletionPTEN-Hemizygous-Wistar
Gene deletionCDKN2B-Homozygous-PubMed=35933914
Gene deletionCDKN2A-HomozygousPossiblePubMed=26870271

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
12,13
D16S539
11,12
D18S51
17,21
D19S433
13
D21S11
29
D2S1338
19
D3S1358
15,18
D5S818
13
D7S820
8
D8S1179
13,15
FGA
21,23
TH01
7,9
TPOX
8,11
vWA
15,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.

Palmieri G.

Oncol. Rep. 25:1495-1502(2011).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.

Nathanson K.L.

Cancer Res. 68:5743-5752(2008).

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

Dummer R.

Pigment Cell Res. 19:290-302(2006).

High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.

Garrido F.

Cancer Immunol. Immunother. 54:141-148(2005).

Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.

Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.

Oncogene 23:8796-8804(2004).

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Tsao H., Goel V., Wu H., Yang G., Haluska F.G.

J. Invest. Dermatol. 122:337-341(2004).

Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.

Falcinelli S., Zambruno G., D'Atri S.

J. Invest. Dermatol. 115:1000-1007(2000).

Characteristics of cultured human melanocytes isolated from different stages of tumor progression.

Koprowski H.

Cancer Res. 45:5670-5676(1985).

Primary melanoma cells of the vertical growth phase: similarities to metastatic cells.

Clark W.H. Jr., Koprowski H.

J. Natl. Cancer Inst. 74:283-289(1985).

Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor.

Herlyn M., Rodeck U., Koprowski H.

Proc. Natl. Acad. Sci. U.S.A. 83:7197-7200(1986).

Human melanoma: development and progression.";

Herlyn M.

Cancer Metastasis Rev. 9:101-112(1990).